Journal
JOURNAL OF CONTROLLED RELEASE
Volume 345, Issue -, Pages 709-720Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2022.03.049
Keywords
Cisplatin; Drug delivery systems; Drug resistance; Toxicity
Funding
- Japan Science and Technology Agency (JST) [JPMJCE1305]
- Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [20K20209]
- Natural Science Research Project of Colleges and Universities in Anhui Province [KJ2020A0107]
- Project of Introducing High-level Talents [2020rcjj28]
- Grants-in-Aid for Scientific Research [20K20209] Funding Source: KAKEN
Ask authors/readers for more resources
Cisplatin is a successful chemotherapy drug, but its resistance and toxicity limit its clinical application. Targeted nanomedicine offers hope for maximizing efficacy and minimizing toxicity. This article reviews the recent progress and challenges in managing cisplatin resistance and toxicity and highlights future directions for development.
Since its license in 1978, cisplatin has proved to be one of the most successful chemotherapeutic agents in the world. However, two acute challenges facing cisplatin, resistance and toxicity, have resulted in a bottleneck of clinical application. Targeted nanomedicine shows great promise in delivering cisplatin for maximizing efficacy while minimizing off-target toxicity. This article surveyed the recent progress and challenges of targeted nanomedicine in managing resistance and toxicity of cisplatin in both fundamental and clinical aspects. Particularly, we focused on three major mechanisms counteracting cisplatin sensitivity (decreased intracellular accumulation, increased cisplatin deactivation, and enhanced DNA repair/translesion synthesis) and correspondingly highlighted a few representative approaches to increase cisplatin sensitivity through improving the intracellular concentration of cisplatin and implementing combination therapy. Moreover, the requirements for future advancements in cisplatin delivery systems are rendered with emphasis on (i) understanding of nano-bio interaction and post-accumulation biological effects instead of overwhelmingly improving tumor accumulation, (ii) development of stimuli-responsive and/or actively-targeted nanomedicines, (iii) optimization of combination therapy, (iv) novel combinations targeting tumor microenvironment and immunotherapy. We postulate that cisplatin-based nanomedicines will continuously advance and potentially revolutionize oncological treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available